The global progressive multifocal leukoencephalopathy (PML) drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Progressive multifocal leukoencephalopathy (PML) is a rare brain infection that affects the substance in the brain that protects nerve cells. The infection gets worse over time and leads to neurological disabilities. The major factor driving the demand for PML drugs is significant prevalence of this infection across the globe.
According to the National Organization for Rare Disorder (NORD), PML is caused by a virus called JC virus (JCV). JCV is found in 85% of the adult population globally. Additionally, PML occurs in approximately one in 200,000 people. Furthermore, in the US and Europe, an estimated 4,000 people develop PML each year. Hence, the rising prevalence of the infection is driving the demand for progressive multifocal leukoencephalopathy drugs.
To Request a Sample of our Report on Progressive Multifocal Leukoencephalopathy Drug Market: https://www.omrglobal.com/request-sample/progressive-multifocal-leukoencephalopathy-drug-market
Some major players in the market include Pfizer, Inc., F. Hoffman – La Roche AG, and Bristol-Myers Squibb Co., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Cellevolve Bio announced a collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics. The collaboration was aimed to advance a novel off-the-shelf t-cell therapy in the first randomized cell therapy trial for progressive multifocal leukoencephalopathy (PML).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Pfizer, Inc., F. Hoffman – La Roche AG, and Bristol-Myers Squibb Co., among others.
(Get 15% Discount on Buying this Report)
A full Report of Progressive Multifocal Leukoencephalopathy Drug Market is Available @ https://www.omrglobal.com/industry-reports/progressive-multifocal-leukoencephalopathy-drug-market
Global Progressive Multifocal Leukoencephalopathy Drug Market Report by Segment
By Type
- EBT-103
- IKT-01427
- Imatinib Mesylate
- NI-307
- Others
By Application
- Hospital
- Clinic
- Others
Global Progressive Multifocal Leukoencephalopathy Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
